Hodgkin’s Lymphoma – Opportunity Analysis and Forecasts to 2029

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hodgkin’s Lymphoma: Executive Summary

2.1 Moderate Market Growth Expected for Hodgkin’s Lymphoma During 2019–2029

2.2 Drug Developers Focusing On Combination Therapies Featuring Marketed Products with Novel Therapies

2.3 Need for More Effective Therapies to Reduce the Use of Chemotherapy and Delay Stem Cell Transplant is Partially Attainable

2.4 Growth in the 8MM Is Driven by Label Expansions of Existing Therapies and Less Impacted by Novel Agents

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Diagnosis and Symptoms

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Sources Not Used

5.5 Forecast Assumptions and Methods

5.5.1 8MM

5.6 Epidemiological Forecast for HL (2019–2029)

5.6.1 Diagnosed Incident Cases of HL

5.6.2 Diagnosed Incident Cases of Classical HL

5.6.3 Age-Specific Diagnosed Incident Cases of Classical HL

5.6.4 Sex-Specific Diagnosed Incident Cases of Classical HL

5.6.5 Diagnosed Incident Cases of Classical HL by Cancer Stage

5.6.6 Diagnosed Incident Cases of Classical HL by Cancer Subtypes

5.6.7 Five-Year Diagnosed Prevalent Cases of Classical HL

5.6.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant HL

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of the Analysis

5.7.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Treatment Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Longer Remission for Newly Diagnosed Stage III–IV Patients

7.3 Lack of Effective Treatment Options for Transplant Ineligible and/or Fragile Patients

7.4 More Effective Salvage and Pre-Stem Cell Transplant Therapies in the Second Line

7.5 Alternative Therapies to Replace Stem Cell Transplants in the Second Line

8 R&D Strategies

8.1 Overview

8.1.1 Established Therapeutic Targets in HL

8.1.2 Novel Mechanisms of Action and Targets

8.1.3 Exploring Possibilities for Broader Use of Immune Checkpoint Inhibitors in the HL Treatment Paradigm

8.2 Clinical Trials Design

8.2.1 Current Endpoints in HL Clinical Trials

8.2.2 Patient Selection for Clinical Trials

9 Pipeline Assessment

9.1 Late-Stage Agents in the HL Pipeline

9.2 Middle-Stage Agents in the Pipeline

9.3 Innovative Early Stage Approaches

9.3.1 Early Stage Agents in the Pipeline

9.3.2 Re-purposing Previous Pipeline Agents

9.3.3 Cell-Based Drugs in the Pipeline

9.4 The Future of HL Treatment

9.5 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

10.4.4 China

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included In Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Drug Assumptions

11.3.8 Biosimilar Erosion

11.3.9 Pricing Of Pipeline Agents

11.4 Primary Research – Key Opinion Leaders Interviewed For This Report

11.4.1 Key Opinion Leaders

11.5 Primary Research – Prescriber Survey

11.6 About The Authors

11.6.1 Analyst

11.6.2 Reviewer

11.6.3 Therapy Area Director

11.6.4 Epidemiologist

11.6.5 Global Director Of Therapy Analysis And Epidemiology

11.6.6 Global Head And EVP Of Healthcare Operations And Strategy

11.7 About Globaldata

11.8 Contact Us

11.9 Disclaimer

Table 1: Hodgkin’s Lymphoma: Key Metrics in the 8MM

Table 2: Characteristics of the Five Histologic Subtypes of HL

Table 3: Notable Somatic Alterations Identified in RS cells of HL

Table 4: The Lugano Staging Classification of HL

Table 5: Prognostic Risk Factors of HL

Table 6: HL Cancer Stages

Table 7: Risk Factors and Comorbidities for HL

Table 8: Treatment Guidelines for HL

Table 9: Leading Treatments for HL, 2019

Table 10: List of Key Historical Clinical Trials of Marketed Products in HL

Table 11: List of Ongoing Key Clinical Trials for Marketed Products

Table 12: Comparison of Therapeutic Classes in Development for HL, 2019–2029

Table 13: Innovative Early Stage Approaches for HL

Table 14: Drugs in Development for HL, 2020

Table 15: Clinical Benchmark of Key Pipeline Drugs – HL

Table 16: Commercial Benchmark of Key Pipeline Drugs – HL

Table 17: Key Events Impacting Global Sales for HL, 2019–2029

Table 18: HL Global Market – Global Drivers and Barriers, 2019 and 2029

Table 19: HL US Market – Global Drivers and Barriers, 2019 and 2029

Table 20: HL 5EU Market – Global Drivers and Barriers, 2019 and 2029

Table 21: HL Japan Market – Global Drivers and Barriers, 2019 and 2029

Table 22: HL China Market – Global Drivers and Barriers, 2019 and 2029

Table 23: Key Historical and Projected Launch Dates for HL

Table 24: Key Historical and Projected Patent Expiry Dates for HL

Table 25: Adult Average Weight per Country Based on National Studies

Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Sales Forecast by Class for HL in the US in 2019 and 2029

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Adcetris

Figure 3: 8MM, Diagnosed Incidence Rates of CHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009‒2029

Figure 4: Sources Used for Diagnosed Incident Cases of HL, CHL, and NLPHL

Figure 5: Sources Used for Diagnosed Incident Cases of CHL by Stage

Figure 6: Sources Used for Diagnosed Incident Cases of CHL Subtypes

Figure 7: Sources Used for Five-Year Diagnosed Prevalent Cases of CHL

Figure 8: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019

Figure 9: 8MM, Diagnosed Incident Cases of CHL, Both Sexes, All Ages, N, 2019

Figure 10: 8MM, Age-Specific Diagnosed Incident Cases of CHL, Both Sexes, N, 2019

Figure 11: 8MM, Sex-Specific Diagnosed Incident Cases of CHL, All Ages, N, 2019

Figure 12: 8MM, Diagnosed Incident Cases of CHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019

Figure 13: 8MM, Diagnosed Incident Cases of CHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019

Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of CHL, Both Sexes, All Ages, N, 2019 and 2029

Figure 15: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019

Figure 16: Treatment Overview for HL

Figure 17: Unmet Needs and Opportunities in HL

Figure 18: Overview of the Development Pipeline in HL

Figure 19: Key Phase II and III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for HL in the 8MM During the Forecast Period

Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Adcetris

Figure 21: Global (8MM) Sales Forecast by Country for HL in 2019 and 2029

Figure 22: Global (8MM) Sales Forecast by Class for HL in 2019 and 2029

Figure 23: Sales Forecast by Class for HL in the US in 2019 and 2029

Figure 24: Global Sales Forecast by Class in the 5EU for HL in 2019 and 2029

Figure 25: Global Sales Forecast by Class in Japan for HL in 2019 and 2029

Figure 26: Global Sales Forecast by Class in China for HL in 2019 and 2029